Evidence map›Paper›PMID 38581292›Full record

ArticleNeuro-oncology2024

Radical surgical resection with molecular margins is associated with improved survival in IDH wild-type glioblastoma.

Elie Massaad, William J Smith, Joseph Bradley, Eric Esposito, Mihir Gupta, Evan Burns, Ryan Burns, José K Velarde, Inka K Berglar, Rajiv Gupta and 14 more

Open access · greenAbstract read
In one paragraph

Article in Neuro-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Contemporary surgical strategies for resection of intracranial gliomas.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 4 institutions in 1 country.

Elie MassaadDepartment of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
William J SmithDepartment of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
Joseph BradleyDepartment of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
Eric EspositoDepartment of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
Mihir GuptaDepartment of Neurosurgery, Yale New Heaven Health, New Haven, Connecticut, USA.
Evan BurnsJacobs School of Medicine, University of Buffalo, Buffalo, New York, USA.
Ryan BurnsDepartment of Biology, Boston College, Newton, Massachusetts, USA.
José K VelardeDepartment of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
Inka K BerglarDepartment of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Rajiv GuptaDepartment of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Maria Martinez-LageDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Jorg DietrichDepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Jochen K LennerzDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Gavin P DunnDepartment of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
Pamela S JonesDepartment of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
Bryan D ChoiDepartment of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
Albert E KimDepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Matthew FroschDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Fred G BarkerDepartment of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
William T CurryDepartment of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
Bob S CarterDepartment of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
Brian V NahedDepartment of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
Daniel P CahillDepartment of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
Ganesh M ShankarDepartment of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
Massachusetts General Hospital · USBoston College · USUniversity at Buffalo, State University of New York · USYale New Haven Health System · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Liquid Biopsy for treatment stratification of IDH1.R132H and EGFRvIII mutant gliomasU01CA230697 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CARTER, BOB S, SKOG, JOHAN · 2018 to 2022
$4.0M
Perioperative Targeted Genotyping in GliomaK08NS107634 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI SHANKAR, GANESH · 2019 to 2023
$966k
NCATS NIH HHS UL1 TR001863NCI NIH HHS 5U01CA230697NCI NIH HHS U01 CA230697NIH HHSNINDS NIH HHS 1K08NS107634-01A1NINDS NIH HHS K08 NS107634
6 · The paper itself

Abstract

backgroundSurvival is variable in patients with glioblastoma IDH wild-type (GBM), even after comparable surgical resection of radiographically detectable disease, highlighting the limitations of radiographic assessment of infiltrative tumor anatomy. The majority of postsurgical progressive events are failures within 2 cm of the resection margin, motivating supramaximal resection strategies to improve local control. However, which patients benefit from such radical resections remains unknown.

methodsWe developed a predictive model to identify which IDH wild-type GBMs are amenable to radiographic gross-total resection (GTR). We then investigated whether GBM survival heterogeneity following GTR is correlated with microscopic tumor burden by analyzing tumor cell content at the surgical margin with a rapid qPCR-based method for detection of TERT promoter mutation.

resultsOur predictive model for achievable GTR, developed on retrospective radiographic and molecular data of GBM patients undergoing resection, had an area under the curve of 0.83, sensitivity of 62%, and specificity of 90%. Prospective analysis of this model in 44 patients found that 89% of patients were correctly predicted to achieve a residual volume (RV) < 4.9cc. Of the 44 prospective patients undergoing rapid qPCR TERT promoter mutation analysis at the surgical margin, 7 had undetectable TERT mutation, of which 5 also had a GTR (RV < 1cc). In these 5 patients at 30 months follow-up, 75% showed no progression, compared to 0% in the group with TERT mutations detected at the surgical margin (P = .02).

conclusionsThese findings identify a subset of patients with GBM that may derive local control benefits from radical resection to undetectable molecular margins.

Indexed as

Brain NeoplasmsGlioblastomaIsocitrate DehydrogenaseMargins of ExcisionMutationAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedNeurosurgical ProceduresPrognosisPromoter Regions, GeneticProspective StudiesIDH1 protein, humanIsocitrate DehydrogenaseTelomeraseTERT protein, humanextent of resectionGBMpostoperative survivalsupramaximal resectionTERT promoter

Identifiers

PMID38581292
PMCPMC11376447
OpenAlexW4394065257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.